Long-term hydronidone treatment for liver fibrosis in chronic hepatitis B
Treatments studied
Part of Digestive system clinical trials.
This study tests a long-term treatment with hydronidone capsules to see if it can help reduce liver scarring (fibrosis) in people with chronic hepatitis B. It aims to improve liver health and prevent progression to more serious liver disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have had chronic hepatitis B for at least 6 months.
- You have not taken antiviral medication for hepatitis B, or you have been on a stable antiviral treatment for at least 6 months.
- Your liver stiffness measurement (a non-invasive test) is above a certain level, or a liver biopsy shows significant scarring.
- Your liver enzyme (ALT) level is less than 8 times the upper limit of normal.
- You have not used certain Chinese herbal medicines with anti-fibrotic effects in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether hydronidone capsules can help people with long-term hepatitis B–related liver scarring (fibrosis). It aims to track whether treatment reduces or delays serious liver complications over time.
This study looks at long-term outcomes in people with chronic hepatitis B who take antiviral medicines or receive interferon. It may help doctors understand which treatments work best over time and who is most likely to benefit.
This trial studies what happens to people with hepatitis B who have hepatitis B surface antigen for more than 6 months, are “HBeAg-negative,” and have certain blood and liver-scarring levels despite normal or near-normal liver inflammation. It may help doctors understand the best care for this specific group before clear treatment phases.
This study tests a new medicine called Hepalatide for people with chronic hepatitis D, a serious liver infection. It aims to see if the drug can reduce the virus and improve liver health. You may be eligible if you have both hepatitis B and D and are on stable hepatitis B treatment.
This early-phase study is testing a treatment approach for people with alcoholic hepatitis (liver inflammation caused by heavy alcohol use). It may help by improving liver function and outcomes in people who meet specific lab and health criteria.
This trial tests a new investigational drug called AHB-171 for people with chronic hepatitis B who are already stable on standard antiviral therapy. It aims to see if the drug is safe and may help control the virus better.
Hear when a new Liver Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.